Search and analyze individual stocks with comprehensive metrics
Glenmark Pharmaceuticals Limited
Fundamental Score
Glenmark Pharmaceuticals Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of GLENMARK across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (15.79%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (16.00%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (8.66x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Institutional Confidence (FII+DII: 38.26%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 42.71x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-23.49%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Limited Growth History (4.60% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Negative Free Cash Flow (₹-1885.64 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Glenmark Pharmaceuticals Limited
About GLENMARK
Company Details
Market Information
Performance
GLENMARK Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of GLENMARK?
GLENMARK is currently trading at ₹2018.60 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of GLENMARK shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of GLENMARK and what does it mean?
GLENMARK has a P/E ratio of 42.71x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹43 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is GLENMARK performing according to Bull Run's analysis?
GLENMARK has a Bull Run fundamental score of 42.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 15.79%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does GLENMARK belong to?
GLENMARK operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Glenmark Pharmaceuticals Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for GLENMARK?
GLENMARK has an ROE of 15.79%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Glenmark Pharmaceuticals Limited generates profits from shareholders' equity. An ROE of 16% means the company generates ₹16 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is GLENMARK's debt-to-equity ratio and what does it indicate?
GLENMARK has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk. This means the company has ₹28 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is GLENMARK's dividend yield and is it a good dividend stock?
GLENMARK offers a dividend yield of 0.12%, which means you receive ₹0.12 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has GLENMARK grown over the past 5 years?
GLENMARK has achieved 5-year growth rates of: Sales Growth 4.60%, Profit Growth 11.77%, and EPS Growth 11.77%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in GLENMARK and why does it matter?
Promoters hold 46.65% of GLENMARK shares, with 0.00% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does GLENMARK compare with its industry peers?
GLENMARK trades at P/E 42.71x vs industry average 33.97x, with ROE of 15.79% and ROCE of 19.40%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether GLENMARK is outperforming its competitive set in profitability, growth, and valuation metrics.
What is GLENMARK's market capitalization and what category does it fall into?
GLENMARK has a market capitalization of ₹56923 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for GLENMARK?
Key ratios for GLENMARK: ROE 15.79% (Excellent), ROCE 19.40%, P/E 42.71x, Debt-to-Equity 0.28, Interest Coverage 8.66x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is GLENMARK stock and what is its beta?
GLENMARK has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for GLENMARK?
GLENMARK has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹2018.60, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in GLENMARK?
Key risks for GLENMARK include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.28), and operational challenges. The stock has a Fundamental Score of 42.4/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is GLENMARK's operating profit margin and how has it trended?
GLENMARK has a 5-year average Operating Profit Margin (OPM) of 16.00%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is GLENMARK's quarterly performance in terms of sales and profit growth?
GLENMARK's recent quarterly performance shows YoY Sales Growth of 0.62% and YoY Profit Growth of -23.49%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in GLENMARK?
GLENMARK has FII holding of 20.62% and DII holding of 17.64%, totaling 38.26% institutional ownership. This institutional participation level shows the confidence of professional money managers. Significant FII holding suggests global investor confidence and potential for index inclusion. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.